Literature DB >> 21561248

NOD2 signaling contributes to the innate immune response against helper-dependent adenovirus vectors independently of MyD88 in vivo.

Masataka Suzuki1, Racel Cela, Terry K Bertin, Gautam Sule, Vincenzo Cerullo, John R Rodgers, Brendan Lee.   

Abstract

We previously demonstrated that Toll-like receptor/myeloid differentiation primary response gene 88 (MyD88) signaling is required for maximal innate and acquired [T helper cell type 1 (Th1)] immune responses following systemic administration of helper-dependent adenoviral vectors (HDAds). However, MyD88-deficient mice injected with HDAdLacZ exhibited only partial reduction of innate immune cytokine expression compared with wild-type mice, suggesting MyD88-independent pathways also respond to HDAds. We now show that NOD2, a nucleotide-binding and oligomerization domain (NOD)-like receptor known to detect muramyl dipeptides in bacterial peptidoglycans, also contributes to innate responses to HDAds, but not to humoral or Th1 immune responses. We established NOD2/MyD88 double-deficient mice that, when challenged with HDAds, showed a significant reduction of the innate response compared with mice deficient for either gene singly, suggesting that NOD2 signaling contributes to the innate response independently of MyD88 signaling following systemic administration of HDAds. In addition, NOD2-deficient mice exhibited significantly higher transgene expression than did wild-type mice at an early time point (before development of an acquired response), but not at a later time point (after development of an acquired response). These results indicate that the intracellular sensor NOD2 is required for innate responses to HDAds and can limit transgene expression during early phases of infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21561248      PMCID: PMC3177951          DOI: 10.1089/hum.2011.002

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  51 in total

1.  Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways.

Authors:  Jiangao Zhu; Xiaopei Huang; Yiping Yang
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

2.  Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator.

Authors:  Marcelo Nociari; Oksana Ocheretina; John W Schoggins; Erik Falck-Pedersen
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

Review 3.  Intracellular NOD-like receptors in host defense and disease.

Authors:  Thirumala-Devi Kanneganti; Mohamed Lamkanfi; Gabriel Núñez
Journal:  Immunity       Date:  2007-10       Impact factor: 31.745

4.  One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications.

Authors:  Carlos Barcia; Maximiliano Jimenez-Dalmaroni; Kurt M Kroeger; Mariana Puntel; Alison J Rapaport; Daniel Larocque; Gwendalyn D King; Stephen A Johnson; Chunyan Liu; Weidong Xiong; Marianela Candolfi; Sonali Mondkar; Philip Ng; Donna Palmer; Maria G Castro; Pedro R Lowenstein
Journal:  Mol Ther       Date:  2007-09-25       Impact factor: 11.454

5.  Antigen-specific tolerance of human alpha1-antitrypsin induced by helper-dependent adenovirus.

Authors:  V Cerullo; W McCormack; M Seiler; V Mane; R Cela; C Clarke; J R Rodgers; B Lee
Journal:  Hum Gene Ther       Date:  2007-12       Impact factor: 5.695

6.  A quantitative assay for measuring clearance of adenovirus vectors by Kupffer cells.

Authors:  Jeffrey S Smith; Zhili Xu; Andrew P Byrnes
Journal:  J Virol Methods       Date:  2007-09-11       Impact factor: 2.014

7.  Early STAT1 activation after systemic delivery of HSV amplicon vectors suppresses transcription of the vector-encoded transgene.

Authors:  Masataka Suzuki; E Antonio Chiocca; Yoshinaga Saeki
Journal:  Mol Ther       Date:  2007-07-24       Impact factor: 11.454

8.  NOD2: a potential target for regulating liver injury.

Authors:  Mathilde Body-Malapel; Sébastien Dharancy; Dominique Berrebi; Alexandre Louvet; Jean-Pierre Hugot; Dana J Philpott; Marco Giovannini; Fabrice Chareyre; Gilles Pages; Emilie Gantier; Stephen E Girardin; Irène Garcia; Sylvie Hudault; Filoména Conti; Philippe J Sansonetti; Mathias Chamaillard; Pierre Desreumaux; Laurent Dubuquoy; Philippe Mathurin
Journal:  Lab Invest       Date:  2008-01-28       Impact factor: 5.662

9.  Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors.

Authors:  Tomoko Yamaguchi; Kenji Kawabata; Naoya Koizumi; Fuminori Sakurai; Kazuko Nakashima; Haruna Sakurai; Tomomi Sasaki; Naoki Okada; Koichi Yamanishi; Hiroyuki Mizuguchi
Journal:  Hum Gene Ther       Date:  2007-08       Impact factor: 5.695

10.  Pannexin-1-mediated intracellular delivery of muramyl dipeptide induces caspase-1 activation via cryopyrin/NLRP3 independently of Nod2.

Authors:  Noemí Marina-García; Luigi Franchi; Yun-Gi Kim; Douglas Miller; Christine McDonald; Geert-Jan Boons; Gabriel Núñez
Journal:  J Immunol       Date:  2008-03-15       Impact factor: 5.422

View more
  14 in total

1.  Cytokine-conditioned dendritic cells induce humoral tolerance to protein therapy in mice.

Authors:  Gautam Sule; Masataka Suzuki; Kilian Guse; Racel Cela; John R Rodgers; Brendan Lee
Journal:  Hum Gene Ther       Date:  2012-05-11       Impact factor: 5.695

Review 2.  Innate immunity to adenovirus: lessons from mice.

Authors:  Svetlana Atasheva; Jia Yao; Dmitry M Shayakhmetov
Journal:  FEBS Lett       Date:  2019-12-08       Impact factor: 4.124

Review 3.  Improving Molecular Therapy in the Kidney.

Authors:  Jeffrey D Rubin; Michael A Barry
Journal:  Mol Diagn Ther       Date:  2020-08       Impact factor: 4.074

Review 4.  New insights into Nod-like receptors (NLRs) in liver diseases.

Authors:  Tao Xu; Yan Du; Xiu-Bin Fang; Hao Chen; Dan-Dan Zhou; Yang Wang; Lei Zhang
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-03-10

5.  An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance.

Authors:  Vincenzo Cerullo; Iulia Diaconu; Valentina Romano; Mari Hirvinen; Matteo Ugolini; Sophie Escutenaire; Sirkka-Liisa Holm; Anja Kipar; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2012-07-24       Impact factor: 11.454

6.  Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity.

Authors:  Michael Brown
Journal:  Cancer Treat Res       Date:  2022

7.  Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo.

Authors:  Masataka Suzuki; Terry K Bertin; Geoffrey L Rogers; Racel G Cela; Irene Zolotukhin; Donna J Palmer; Philip Ng; Roland W Herzog; Brendan Lee
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

8.  Helper-Dependent Adenoviral Vectors.

Authors:  Amanda Rosewell; Francesco Vetrini; Philip Ng
Journal:  J Genet Syndr Gene Ther       Date:  2011-10-29

9.  The role of endosomal escape and mitogen-activated protein kinases in adenoviral activation of the innate immune response.

Authors:  Jeffrey S Smith; Zhili Xu; Jie Tian; Donna J Palmer; Philip Ng; Andrew P Byrnes
Journal:  PLoS One       Date:  2011-10-27       Impact factor: 3.240

10.  Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy.

Authors:  Lisa Farzad; Vincenzo Cerullo; Shigeki Yagyu; Terry Bertin; Akseli Hemminki; Cliona Rooney; Brendan Lee; Masataka Suzuki
Journal:  Mol Ther Oncolytics       Date:  2014-12-17       Impact factor: 7.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.